Stockscreener 앱 받기
22.83
1.11%
0.25
시간 외 거래:
22.67
-0.16
-0.70%
전일 마감가:
$22.58
열려 있는:
$22.25
하루 거래량:
855.59K
Relative Volume:
0.94
시가총액:
$1.35B
수익:
$13.05M
순이익/손실:
$-60.54M
주가수익비율:
-19.68
EPS:
-1.16
순현금흐름:
$-37.82M
1주 성능:
-3.10%
1개월 성능:
-6.63%
6개월 성능:
-42.01%
1년 성능:
-37.43%
1일 변동 폭
$22.25
$23.61
1주일 범위
$22.25
$26.50
52주 변동 폭
$22.25
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
명칭
Janux Therapeutics Inc
전화
(858) 751-4493
주소
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
JANX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
22.83 | 1.43B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Raymond James | Outperform |
| 2024-12-03 | 재확인 | BTIG Research | Buy |
| 2024-12-03 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-22 | 개시 | Leerink Partners | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Perform |
| 2024-03-21 | 개시 | BTIG Research | Buy |
| 2024-03-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 개시 | Wedbush | Outperform |
| 2022-11-14 | 개시 | William Blair | Outperform |
모두보기
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Janux Therapeutics Earns Buy Rating Amid Promising Pipeline and Strong Financial Position. - AInvest
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position - TipRanks
Janux Therapeutics 2024 Q3 Earnings Widening Losses Amidst Revenue Decline - AInvest
Janux Therapeutics stock hits 52-week low at 22.25 USD - Investing.com
Janux Therapeutics stock hits 52-week low at 22.25 USD By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $59 to $100 - 富途牛牛
Janux (JANX) R&D Soars Revenue Misses - AOL.com
Janux Therapeutics Reports Q2 2025 Financial Results - TipRanks
Janux Therapeutics 2024 Q3 Earnings Deepening Losses Amid Pipeline Progress - AInvest
Janux Therapeutics Inc. Receives Buy Rating for Promising Pipeline and Financial Stability - AInvest
Optimistic Outlook for Janux Therapeutics: Strong Cash Position and Promising ‘007 Program Drive Buy Rating - TipRanks
Optimistic Buy Rating for Janux Therapeutics Inc. Driven by Promising R&D, Strong Cash Position, and Strategic Expansion - TipRanks
Promising Pipeline and Financial Stability Support Buy Rating for Janux Therapeutics Inc - TipRanks
Janux Therapeutics reports Q2 EPS (55c), consensus (47c) - TipRanks
Janux Therapeutics Reports Q2 FY25 Financial Results, $996mln Cash, Milestone Payment from Merck. - AInvest
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Yahoo Finance
Janux Therapeutics reaches clinical milestone in Merck TRACTr collaboration - TipRanks
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Business Wire
Is Janux Therapeutics Inc. a growth stock or a value stockSuperior return velocity - Jammu Links News
What analysts say about Janux Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
What are the latest earnings results for Janux Therapeutics Inc.Build wealth faster with consistent investment plans - Jammu Links News
Should I hold or sell Janux Therapeutics Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What drives Janux Therapeutics Inc. stock priceExplosive trading growth - Jammu Links News
Janux Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with expert advice - Jammu Links News
How does Janux Therapeutics Inc. generate profit in a changing economyMaximize your gains with professional insights - Jammu Links News
Is Janux Therapeutics Inc. stock overvalued or undervaluedMaximize gains with data-driven stock picks - Jammu Links News
What makes Janux Therapeutics Inc. stock price move sharplyAccess powerful market insights for free - Jammu Links News
What are analysts’ price targets for Janux Therapeutics Inc. in the next 12 monthsUnlock your portfolio’s hidden potential - Jammu Links News
How does Janux Therapeutics Inc. compare to its industry peersAccelerated financial growth - Jammu Links News
Can Janux Therapeutics Inc. Regain Momentum After BreakdownReal Trader Watchlist of Hot Stocks Released - metal.it
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification - TipRanks
Why Janux Therapeutics Inc. stock attracts strong analyst attentionTriple Return Setup With Risk Control Explained - metal.it
Janux Therapeutics Receives Buy Rating from Leerink Partners Analyst Jeffrey La Rosa - AInvest
Why did JANX's operating expenses surge in Q3 2024? - AInvest
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Praise Ionis Pharmaceuticals and Janux Therapeutics for Bright Healthcare Futures - AInvest
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Combining machine learning predictions for Janux Therapeutics Inc. Yield Curve Outlook and Long-Term Implication Summary - metal.it
What is the dividend policy of Janux Therapeutics Inc. stockSuperior stock selection - Jammu Links News
Janux Therapeutics Inc (JANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):